争议事件
以下收录公开来源中与该品牌相关的争议事件。列出一条并不表示过错已经证实。
返回词条共 1 条
2020
United Therapeutics就Tyvaso专利起诉Liquidia
提起诉讼
United Therapeutics在美国联邦地区法院起诉Liquidia，指控其侵犯与Tyvaso产品相关的专利。诉讼涉及Liquidia申请FDA批准上市的LIQ861；报道未称法院已对相关指控作出认定。
来源摘录
United Therapeutics Corporation (Nasdaq: UTHR) announced today that it has filed a lawsuit in the U.S. District Court for the District of Delaware against Liquidia Technologies, Inc. (Liquidia) for infringement of the following patents relating to United Therapeutics' product Tyvaso® (treprostinil) Inhalation Solution: U.S. Patent Nos. 9,604,901 (the '901 patent) and 9,593,066 (the '066 patent), both of which expire in December 2028.
The lawsuit is based on a New Drug Application (NDA) filed by Liquidia with the U.S. Food and Drug Administration (FDA) requesting approval to market LIQ861, a dry powder inhalation formulation of treprostinil.